UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): December 14, 2022

COMMUNITY HEALTHCARE TRUST INCORPORATED

(Exact Name of Registrant as Specified in its Charter)

(615) 771-3052

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

Item 1.01     Entry into a Material Definitive Agreement.

On December 14, 2022, Community Healthcare Trust Incorporated (the “Company”), as borrower, entered into a first amendment (the “First Amendment”) to the third amended and restated credit agreement (the “Credit Agreement”) with a syndicate of lenders, under which Truist Bank serves as administrative agent.

The First Amendment is described in further detail in Item 2.03 below.

The summary of the First Amendment contained herein does not purport to be complete and is qualified in its entirety by reference to the full text of the First Amendment, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.1.

Item 2.03     Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information reported under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

The First Amendment amends the Credit Agreement to, among other things, (i) establish a new seven-year and three-month term loan facility in the aggregate principal amount of $150.0 million (the “A-5 Term Loan”), and (ii) replace the London interbank offered rate (“LIBOR”) as a benchmark interest rate for loans under the Credit Agreement with the secured overnight financing rate administered by the Federal Reserve Bank of New York (“SOFR”). The proceeds of the A-5 Term Loan were used to repay the existing five-year term loan facility in the aggregate principal amount of $50 million (the “A-2 Term Loan”) and to repay $85 million aggregate principal amount of loans outstanding under the existing revolving credit facility (the “Revolving Facility”), with the balance of the proceeds expected to be used to fund acquisitions that are anticipated to close prior to the end of 2022.

As amended by the First Amendment, the Credit Agreement allows the Company to borrow, through the accordion feature, up to $700.0 million, including the ability to add and fund incremental term loans, and includes the following (the “Credit Facility”):

Amounts outstanding under the Revolving Credit Facility bear annual interest at a floating rate that is based, at the Company’s option, on either: (i) adjusted term SOFR or adjusted daily simple SOFR (each as defined in the Credit Agreement) plus 1.25% to 1.90% or (ii) a base rate (as defined in the Credit Agreement) plus 0.25% to 0.90% in each case, depending upon the Company’s leverage ratio. Amounts outstanding under the A-3 Term Loan, A-4 Term Loan and A-5 Term Loan bear annual interest at a floating rate that is based, at the Company’s option, on either: (i) adjusted term SOFR or adjusted daily simple SOFR (each as defined in the Credit Agreement) plus 1.65% to 2.30% or (ii) a base rate (as defined in the Credit Agreement) plus 0.65% to 1.30%, in each case, depending upon the Company’s leverage ratio. The Company previously entered into interest rate swaps to fix the interest rates on the A-3 Term Loan and A-4 Term Loan. The existing interest rate swap on the refinanced A-2 Term Loan in the amount of $50 million will be applicable to the A-5 Term Loan until its maturity, and the Company intends to enter into additional interest rate swaps to fix the interest rate on the balance of the A-5 Term Loan.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.